Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Blood|May 5, 2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphomaJohn Kuruvilla, Michael Savona, Rachid Baz, et al.
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2023
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with MyelomaCiara L Freeman, Reginald Atkins, Indumathy Varadarajan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple MyelomaIrene M Ghobrial, Chia-Jen Liu, Robert A Redd, et al.
Blood Advances|May 2, 2022
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myelomaLauren C Peres, Christelle M Colin-Leitzinger, Mingxiang Teng, et al.
Cancer Research|April 13, 2017
An <i>Ex Vivo</i> Platform for the Prediction of Clinical Response in Multiple MyelomaAriosto Silva, Maria C Silva, Praneeth Sudalagunta, et al.
The Lancet. Oncology|December 9, 2016
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyNancy K Gillis, Markus Ball, Qing Zhang, et al.
British Journal of Haematology|March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaTaiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Pageof 9